Zynex Bankruptcy Sparks Securities Class Action After $85M Fraud Settlement

Zynex, Inc. ($ZYXI / $ZYXIQ) faces a major securities class action lawsuit following its delisting and Chapter 11 bankruptcy filing, in what represents a dramatic collapse for the medical device company. The lawsuit, filed by law firm Hagens Berman, alleges that the company systematically engaged in an 'oversupplying' scheme designed to overbill government and private healthcare payors by shipping excessive medical supplies without medical necessity. The action comes after former CEO Thomas Sandgaard and former COO Anna Lucsok were indicted on healthcare and securities fraud charges, and the company agreed to forfeit over $85 million to settle federal fraud allegations.

The Collapse: Fraud Allegations and Financial Reckoning

The downfall of Zynex accelerated dramatically after Tricare, the Department of Defense's health insurance program, suspended payments to the company—representing its largest payor. This suspension effectively cut off a critical revenue stream and triggered a cascade of financial distress that culminated in the bankruptcy filing.

The core allegations paint a picture of systematic fraudulent conduct:

• Systematic oversupply scheme: The company allegedly shipped medical supplies in quantities far exceeding medical necessity
• Intentional overbilling: The strategy targeted both government programs like Tricare and private insurance payors
• Executive involvement: Former leadership directly implicated in healthcare and securities fraud
• Massive financial penalty: The company forfeited over $85 million to resolve federal fraud allegations
• Criminal indictments: Sandgaard and Lucsok face criminal charges related to the fraudulent conduct

The $85 million settlement represents a substantial portion of what was once considered a growing telehealth and medical device company. For context, this settlement amount signals that federal regulators uncovered significant, widespread misconduct spanning multiple billing cycles and affecting numerous payors.

Market Context: Red Flags in Medical Device Sector

The Zynex collapse occurs within a broader environment of increased scrutiny of medical device and telehealth companies. The healthcare sector has witnessed regulatory intensification following high-profile cases of billing fraud and improper marketing practices.

Zynex had positioned itself as a provider of electrotherapy devices and remote monitoring solutions, operating in a competitive landscape alongside larger medical device manufacturers. The company's strategy of aggressive billing practices ultimately exposed it to regulatory risk that proved fatal.

Several industry dynamics contributed to the vulnerability:

• Telehealth boom scrutiny: Government agencies have increased audits of telehealth and remote monitoring providers that emerged during the pandemic
• Medicare/Tricare focus: Federal programs have prioritized investigating billing anomalies and potential fraud schemes
• Competitive pressure: Smaller medical device companies face margin pressures that can incentivize problematic billing practices
• Regulatory enforcement wave: The Department of Justice and HHS Office of Inspector General have prioritized healthcare fraud cases

This enforcement action demonstrates that even companies operating in growth sectors face existential risk if they engage in systematic billing fraud.

Investor Implications: Significant Losses and Legal Recourse

For Zynex shareholders, the implications are severe. The company's delisting and bankruptcy filing represent a near-total loss of equity value. However, the class action lawsuit provides a potential avenue for recovery, albeit likely to be limited.

Investors who purchased Zynex stock between February 25, 2021, and December 15, 2025, are eligible to participate in the class action. The deadline to request lead plaintiff status is April 21, 2026—a critical date for investors seeking representation in the litigation.

Key considerations for affected shareholders:

• Bankruptcy priority: In Chapter 11 proceedings, equity holders typically rank last in the capital structure, often receiving little to nothing after secured creditors and bondholders are paid
• Class action recovery: While available, recovery from class actions against bankrupt companies is frequently minimal, often measured in cents per share
• Legal fees: Typical class action settlements allocate substantial portions to attorney fees and administrative costs
• Timeline: Securities litigation against bankrupt companies often takes years to resolve

The extended period between the alleged fraudulent conduct and discovery—shareholders purchased stock over a four-year window—suggests the fraud may have persisted and evolved over time, affecting multiple investor cohorts.

The Road Ahead: Bankruptcy Proceedings and Litigation

As Zynex moves through Chapter 11 bankruptcy, the company's assets will be liquidated to satisfy creditor claims in accordance with bankruptcy law's strict priority system. Meanwhile, the securities class action will proceed through federal court, with investors bearing the burden of proving that company misstatements or omissions caused their losses.

The criminal indictments against Sandgaard and Lucsok may provide evidentiary support for the civil class action, as criminal findings of fact can sometimes assist civil litigants. However, criminal cases and civil litigation operate under different burdens of proof and may reach different conclusions.

The case underscores broader lessons for investors in smaller medical device and telehealth companies: aggressive business models targeting government payors carry regulatory risk, management integrity is paramount, and rapid growth claims deserve scrutiny regarding their underlying revenue quality. For shareholders of Zynex, the path to potential recovery is long and uncertain, with the April 21, 2026 deadline representing the critical window to assert legal claims.